Photo from Tom Powles/X
May 23, 2024, 13:33
Tom Powles: Debate about activity of neoadjuvant vs adjuvant vs both is ongoing
Tom Powles, Director of Barts Cancer Center, shared a post on X:
“Neoadjuvant chemo/nivolumab with adjuvant nivolumab show high DFS (HR 0.58) and high pCR in NSCLC.
23% and 35% didn’t have surgery/adjuvant nivolumab respectively.
Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durvalumab/nivolumab/pembrolizumab) awaited.”
Source: Tom Powles/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 20, 2024, 01:27
Dec 20, 2024, 00:41
Dec 20, 2024, 00:26
Dec 19, 2024, 21:47
Dec 19, 2024, 21:43
Dec 19, 2024, 21:39
Dec 19, 2024, 21:34
Dec 19, 2024, 21:31
Dec 19, 2024, 21:27